Didier LACOMBE
University Hospital Bordeaux, France · Service de Génétique Médicale/Bordeaux
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Didier LACOMBE as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:52 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT01619644 · Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic TrialUniversity Hospital, Bordeaux · completed · Rubinstein-Taybi Syndrome · principal investigator
- N/ANCT00213811 · Bardet-Biedl Syndrome Study: Clinical and Genetic Epidemiology Study in AdultsUniversity Hospital, Strasbourg, France · completed · Bardet-Biedl Syndrome, Orphan Diseases · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:52 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:52 UTC. The ranking covers the 200 most relevant of 55 PubMed records, and a shared surname and initials can bring in a namesake. All 55 on PubMed
- Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N Engl J Med · 200518,057 citationsRCR 417.1
- 6,475 citationsRCR 163.8
- Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.J Clin Oncol · 2013902 citationsRCR 28.2
- 571 citationsRCR 14.0
- Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.J Clin Oncol · 2009456 citationsRCR 10.5
- Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.Lancet Oncol · 2008433 citationsRCR 11.3
- Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.J Clin Oncol · 2006390 citationsRCR 9.8
- Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.Lancet Oncol · 2016383 citationsRCR 13.3
- 315 citationsRCR 8.1
- Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.Neurology · 2011218 citationsRCR 6.0